Oropharyngeal squamous cell carcinoma (SCC) is a common type of head and neck cancer often linked to tobacco, alcohol use, and, in youngers, HPV infection. Standard care for locally advanced SCC involves radiotherapy (RT) and cisplatin, (total doses of 66–70Gy in 30–35fractions). However, some patients with significant comorbidities cannot tolerate chemotherapy, requiring alternative approaches. We present a case of a 66-year-old male with p16-negative oropharyngeal SCC and bulky cervical nodal metastasis, ineligible for chemotherapy.

The patient was treated using adaptive volumetric modulated arc therapy (VMAT) with simultaneous integrated boost (SIB) and central gross tumor volume (GTV) dose escalation. This approach delivered up to 72Gy to the central GTV in 30 fractions; 66 Gy in 30 fractions to the high-risk area; 60Gy in 30 fractions to the intermediate-risk area; 54 Gy in 30 fractions to the low-risk area.

An epithelolysis (grade 3) led to a four-day treatment pause. A mid-treatment CT showed tumor shrinkage, reducing the nodal GTV volume from 107to 33cc, prompting adaptive planning to optimize dose distribution and reduce toxicity. The patient completed RT without further interruptions. At six months post-treatment, no recurrence or severe toxicities were detected and four years post-treatment, the patient remains in complete remission without significant late toxicity.

This case demonstrates the effectiveness of VMAT with SIB in delivering accelerated radiotherapy to a bulky nodal lesion in a patient with p16-negative oropharyngeal SCC unfit for chemotherapy; This allowed for tumor control while minimizing exposure to critical structure.

The primary aims of this multicenter, prospective observational study were to investigate spiritual well-being, resilience, and psychosocial distress in an Italian sample of glioblastoma patients undergoing radiochemotherapy. The secondary aim was to explore the influence of demographic, clinical, and psychological characteristics on survival.

The assessment was conducted only once, within the first week of radiochemotherapy treatment. Spiritual well-being was evaluated by the Functional Assessment of Chronic Illness Therapy-Spiritual Well-being (FACIT-Sp-12), and religious/spiritual beliefs and practices were evaluated by the System of Belief Inventory. Resilience was evaluated by the Connor−Davidson Resilience Scale (CD-RISC). Psychosocial distress was evaluated the by Distress Thermometer and Hospital Anxiety Depression Scale. We conducted an univariable analysis of overall survival (OS) using data from the most recent follow-up available, considering demographic and clinical variables that could influence survival. Follow-up was defined as either the time of death or the latest follow-up visit recorded.

We recruited 104 patients, and the median follow-up time was 18.3 months. “Distressed” patients had lower scores than “not distressed” patients on the FACIT-Sp-12 and CD-RISC. While OS was not significant according to the FACIT-Sp-12 threshold, the Kaplan−Meier log-rank test was 0.05 according to the CD-RISC threshold. Among demographic variables, age showed significant associations with OS (p = 0.011). Resilience showed significant associations with OS (p = 0.025).

Data showed that high spiritual well-being was associated with high resilience and an absence of psychosocial distress in our sample of glioblastoma patients undergoing radiochemotherapy. Patients with greater resilience survived longer than those with lesser resilience. Profiling spiritual well-being and resilience in glioblastoma patients undergoing radiochemotherapy can be seen as a resource to identify novel characteristics to improve clinical take-in-charge of glioblastoma patients.